Shares of PROCEPT BioRobotics (NASDAQ: PRCT) plummeted 5.80% on Tuesday following the release of the company's third-quarter earnings report and 2026 revenue guidance. Despite beating analyst expectations for Q3, the surgical robotics company's forward-looking projections appear to have dampened investor enthusiasm.

PROCEPT BioRobotics reported Q3 revenue of $83.327 million, surpassing the analyst estimate of $80.9 million. The company's adjusted EBITDA loss of $7.395 million also outperformed expectations, coming in better than the anticipated loss of $10.2 million. However, these positive results were overshadowed by concerns about future growth.

While the company maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, it was the newly issued fiscal year 2026 revenue guidance that seemed to disappoint investors. PROCEPT BioRobotics projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential deceleration in growth appears to be the primary factor behind the stock's sharp decline.

The market's negative reaction suggests that investors were expecting more aggressive growth projections for the coming year, despite the company's continued expansion of its installed base of robotic systems and strong performance in the current fiscal year. As PROCEPT BioRobotics navigates the competitive medical device landscape, investors will likely keep a close eye on the company's ability to maintain its growth trajectory and path to profitability in the face of potentially moderating expansion rates.